AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16207766 — intervention group
Group type: EXPERIMENTAL
Intervention: Statement establishing a personal standard followed by behavior violating that standard
Number of subjects: 0
Study 16207766 — intervention group
Group type: COMPARATOR
Intervention: Behavior violating the standard followed by statement establishing the standard
Number of subjects: 0
Study 11905866 — intervention group
Group type: COMPARATOR
Intervention: Conventional CO2 pneumoperitoneum (CO2 group; N = 47)
Number of subjects: 95
Study 11905866 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal wall lifting (AWL group; N = 48)
Number of subjects: 95
Study 10951430 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg anhydrous theophylline immediate-release (IR) capsules
Number of subjects: 18
Study 7717633 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implant surgery
Number of subjects: 0
Study 7717633 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography scans
Number of subjects: 0
Study 7717633 — intervention group
Group type: COMPARATOR
Intervention: Drill-out procedure
Number of subjects: 0
Study 2007445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin during delivery (500 mg i.v./6 h)
Number of subjects: 121
Study 2007445 — intervention group
Group type: COMPARATOR
Intervention: No chemoprophylaxis (Control)
Number of subjects: 121
Study 2007445 — intervention group
Group type: COMPARATOR
Intervention: Non-carrier women (Control)
Number of subjects: 121
Study 6261926 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and smoked delta-9-tetrahydrocannabinol (THC)
Number of subjects: 8
Study 6261926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31520865 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 92
Study 31520865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM)
Number of subjects: 92
Study 31520865 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 92
Study 26847947 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS)
Number of subjects: 104
Study 26847947 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice
Number of subjects: 104
Study 25886265 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Memory Training plus Treatment as Usual
Number of subjects: 0
Study 25886265 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 0
Study 23370525 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate (up to 4 g/day)
Number of subjects: 78
Study 23370525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 21266141 — intervention group
Group type: EXPERIMENTAL
Intervention: Big Brain Academy (BBA) - computerized cognitive training program
Number of subjects: 45
Study 21266141 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Psychostimulation Program (IPP) - traditional stimulation program
Number of subjects: 45
Study 21266141 — intervention group
Group type: COMPARATOR
Intervention: Control group (EANT) - no treatment
Number of subjects: 45
Study 18635711 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 0
Study 18635711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17887993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 189
Study 17887993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 15472657 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole chewing gum 20 mg/piece (3.6 mg released), administered 4 times daily
Number of subjects: 140
Study 15472657 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentan gel 2.5 g (50 mg released), administered 4 times daily
Number of subjects: 140
Study 15472657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 15472657 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole chewing gum
Number of subjects: 140
Study 11212046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% induction and maintenance with N2O(66%)-O2-sevoflurane 2% (Group III)
Number of subjects: 45
Study 11212046 — intervention group
Group type: COMPARATOR
Intervention: Propofol and fentanyl (Group I)
Number of subjects: 45
Study 11212046 — intervention group
Group type: COMPARATOR
Intervention: Propofol and N2O(66%)-O2-sevoflurane 2% (Group II)
Number of subjects: 45
Study 11212046 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O(66%)-O2-sevoflurane 2% (Group II)
Number of subjects: 45
Study 11212046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% induction and N2O(66%)-O2-sevoflurane 2% (Group III)
Number of subjects: 45
Study 9145895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus rifampin (C + R)
Number of subjects: 40
Study 9145895 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin alone
Number of subjects: 40
Study 7955753 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallbladder ejection fraction in patients with abdominal pain
Number of subjects: 30
Study 7955753 — intervention group
Group type: COMPARATOR
Intervention: Gallbladder ejection fraction in normal controls
Number of subjects: 30
Study 7955753 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallbladder ejection fraction in patients with elevated sphincter pressures
Number of subjects: 30
Study 7955753 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallbladder ejection fraction in patients with normal sphincter pressures
Number of subjects: 30
Study 7955753 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal gallbladder ejection fractions in patients with elevated pressures
Number of subjects: 30
Study 7955753 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal gallbladder ejection fractions in patients with normal pressures
Number of subjects: 30
Study 7955753 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity of gallbladder ejection fraction for detection of elevated pressures
Number of subjects: 30
Study 7955753 — intervention group
Group type: EXPERIMENTAL
Intervention: Specificity of gallbladder ejection fraction for detection of elevated pressures
Number of subjects: 30
Study 7955753 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive predictive value of gallbladder ejection fraction for detection of elevated pressures
Number of subjects: 30
Study 7955753 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between sphincter pressure and gallbladder ejection fraction
Number of subjects: 30
Study 3592880 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotch (1 mL of 100-proof per pound of body weight)
Number of subjects: 17
Study 3592880 — intervention group
Group type: EXPERIMENTAL
Intervention: Vodka (1 mL of 100-proof per pound of body weight)
Number of subjects: 17
Study 3592880 — intervention group
Group type: COMPARATOR
Intervention: Control (orange juice)
Number of subjects: 17
Study 31907537 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain packaging
Number of subjects: 50
Study 31907537 — intervention group
Group type: COMPARATOR
Intervention: Branded packaging
Number of subjects: 50
Study 31907537 — intervention group
Group type: EXPERIMENTAL
Intervention: Low IS smokers
Number of subjects: 50
Study 31907537 — intervention group
Group type: EXPERIMENTAL
Intervention: High IS smokers
Number of subjects: 50
Study 29770445 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based Diabetes Prevention Program (DPP) with financial incentives
Number of subjects: 847
Study 28302178 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser peripheral iridotomy plus laser peripheral iridoplasty (LPI + LPIP)
Number of subjects: 240
Study 28302178 — intervention group
Group type: COMPARATOR
Intervention: Laser peripheral iridotomy (LPI)
Number of subjects: 240
Study 25782894 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard precautions combined with MRSA screening and decolonization
Number of subjects: 4750
Study 25782894 — intervention group
Group type: COMPARATOR
Intervention: Standard precautions alone (control)
Number of subjects: 4750
Study 23719718 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib alaninate 400 mg (Groups A, B, D)
Number of subjects: 24
Study 23719718 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib alaninate 200 mg (Group C)
Number of subjects: 24
Study 23719718 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib alaninate (Groups A, B, D)
Number of subjects: 24
Study 23719718 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib alaninate (Group C)
Number of subjects: 24
Study 20946656 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon-rich artesian aquifer water (SW) (86 mg/L silica)
Number of subjects: 17
Study 20946656 — intervention group
Group type: COMPARATOR
Intervention: Purified water of low-silicon content (PW)
Number of subjects: 17
Study 20946656 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon-rich artesian aquifer water (SW)
Number of subjects: 17
Study 18760000 — intervention group
Group type: EXPERIMENTAL
Intervention: Street- or shelter-based interventions including education, free condom distribution, syringe and needle prescription programs, chest radiography screening for tuberculosis, directly observed therapy for tuberculosis treatment, improvement of personal clothing and bedding hygiene, widespread use of ivermectin for scabies and body louse infestation.
Number of subjects: 0
Study 18760000 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic vaccination against hepatitis B virus, hepatitis A virus, influenza, Streptococcus pneumoniae, and diphtheria.
Number of subjects: 0
Study 16882179 — intervention group
Group type: EXPERIMENTAL
Intervention: Expertise of the doctor
Number of subjects: 119
Study 16882179 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting time
Number of subjects: 119
Study 16882179 — intervention group
Group type: EXPERIMENTAL
Intervention: Thorough care
Number of subjects: 119
Study 16882179 — intervention group
Group type: EXPERIMENTAL
Intervention: Convenience of consultation
Number of subjects: 119
Study 14695072 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on thyroid function, rheumatoid factor tests and urine cultures
Number of subjects: 96
Study 14695072 — intervention group
Group type: COMPARATOR
Intervention: Feedback on lipid and plasma viscosity tests
Number of subjects: 96
Study 10228251 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine sedation
Number of subjects: 70
Study 10228251 — intervention group
Group type: COMPARATOR
Intervention: Sedation as needed
Number of subjects: 70
Study 8558641 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical plus intradermal BCG
Number of subjects: 154
Study 8558641 — intervention group
Group type: COMPARATOR
Intervention: Intravesical BCG only
Number of subjects: 154
Study 8558641 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever after BCG instillation
Number of subjects: 154
Study 8558641 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive purified protein derivative skin test before treatment
Number of subjects: 154
Study 1678761 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple dose cefuroxime
Number of subjects: 415
Study 1678761 — intervention group
Group type: COMPARATOR
Intervention: Single dose cefuroxime
Number of subjects: 415
Study 1678761 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple dose cefuroxime plus metronidazole
Number of subjects: 415
Study 1678761 — intervention group
Group type: COMPARATOR
Intervention: Single dose cefuroxime plus metronidazole
Number of subjects: 415
Study 6138595 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 17
Study 6138595 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 17
Study 3908104 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol treatment
Number of subjects: 0
Study 3908104 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 28649755 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative geriatric assessment followed by tailored intervention
Number of subjects: 122
Study 28649755 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 122
Study 27678079 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone coaching intervention
Number of subjects: 0
Study 27678079 — intervention group
Group type: COMPARATOR
Intervention: Usual diabetes care (control)
Number of subjects: 0
Study 25831700 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg)
Number of subjects: 121
Study 25831700 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (220 mg)
Number of subjects: 121
Study 25831700 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg)
Number of subjects: 121
Study 25831700 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 121
Study 22503941 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal pillows
Number of subjects: 55
Study 22503941 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal masks
Number of subjects: 55
Study 22503941 — intervention group
Group type: COMPARATOR
Intervention: Oronasal masks
Number of subjects: 55
Study 20479419 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² every 3 weeks for four cycles followed by paclitaxel 175 mg/m² every 3 weeks for four cycles (AC->P)
Number of subjects: 1801
Study 20479419 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 50 mg/m² plus paclitaxel 200 mg/m² every 3 weeks for four cycles followed by paclitaxel 80 mg/m² weekly for 12 weeks (AP-WP)
Number of subjects: 1801
Study 18705538 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day oral magnesium citrate supplementation
Number of subjects: 30
Study 18705538 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study 15625087 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocretin-deficient narcoleptic men
Number of subjects: 14
Study 15625087 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study 12872794 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% ibopamine eye drops
Number of subjects: 30
Study 12872794 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 30
Study 10496658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipamorelin at 4.21 nmol/kg over 15 minutes
Number of subjects: 40
Study 10496658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipamorelin at 14.02 nmol/kg over 15 minutes
Number of subjects: 40
Study 10496658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipamorelin at 42.13 nmol/kg over 15 minutes
Number of subjects: 40
Study 10496658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipamorelin at 84.27 nmol/kg over 15 minutes
Number of subjects: 40
Study 10496658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipamorelin at 140.45 nmol/kg over 15 minutes
Number of subjects: 40
Study 8959632 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium mupirocin 2% (Bactroban nasal) applied twice daily for 5 consecutive days every 4 weeks
Number of subjects: 267
Study 8959632 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment applied twice daily for 5 consecutive days every 4 weeks
Number of subjects: 267
Study 8959632 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium mupirocin 2%
Number of subjects: 267
Study 8959632 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 267
Study 2036493 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing SwedeBall at 0 degrees C
Number of subjects: 44
Study 2036493 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing SwedeBall at -7 degrees C
Number of subjects: 44
Study 2036493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedaling at -10 degrees C
Number of subjects: 44
Study 2036493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedaling at 8 degrees C
Number of subjects: 44
Study 2036493 — intervention group
Group type: COMPARATOR
Intervention: Pedaling at 26 degrees C
Number of subjects: 44
Study 6122004 — intervention group
Group type: EXPERIMENTAL
Intervention: Opsonisation of T lymphocytes with 1 mg of the murine monoclonal antibody OKT3 before infusion
Number of subjects: 17
Study 6122004 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic methotrexate
Number of subjects: 17
Study 6122004 — intervention group
Group type: EXPERIMENTAL
Intervention: Opsonisation of T lymphocytes
Number of subjects: 17
Study 31012850 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire tracking in collateral channels during retrograde PCI
Number of subjects: 886
Study 31012850 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction score model for CC GW crossing success
Number of subjects: 886
Study 30940870 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 22
Study 30940870 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 22
Study 28836458 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg
Number of subjects: 414
Study 28836458 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 414
Study 28836458 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 414
Study 27283723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-space injection of dexamethasone (4 mg) with 2% lignocaine and 1:200,000 epinephrine (SS)
Number of subjects: 30
Study 27283723 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of dexamethasone (4 mg) with standard inferior alveolar nerve block (CS)
Number of subjects: 30
Study 25248371 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Number of subjects: 0
Study 25248371 — intervention group
Group type: COMPARATOR
Intervention: Exclusive oral-feeding supply
Number of subjects: 0
Study 22507090 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy with abdominal corset
Number of subjects: 216
Study 22507090 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 216
Study 20234140 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis (6 x 2.0 x 10(9) CFU/kg/day, 12 billion CFU/kg/day)
Number of subjects: 183
Study 20234140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 20234140 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis
Number of subjects: 183
Study 17279004 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum (5 pieces per day)
Number of subjects: 145
Study 17279004 — intervention group
Group type: COMPARATOR
Intervention: Standard oral care
Number of subjects: 145
Study 16218173 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) 400/100 mg twice daily
Number of subjects: 339
Study 16218173 — intervention group
Group type: COMPARATOR
Intervention: Saquinavir/ritonavir (SAQ/r) 1000/100 mg twice daily
Number of subjects: 339
Study 16218173 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 339
Study 16218173 — intervention group
Group type: COMPARATOR
Intervention: Saquinavir/ritonavir (SAQ/r)
Number of subjects: 339
Study 16218173 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) and Saquinavir/ritonavir (SAQ/r)
Number of subjects: 339
Study 11218421 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal exposure to formaldehyde
Number of subjects: 15
Study 11218421 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal exposure to acetaldehyde
Number of subjects: 15
Study 11218421 — intervention group
Group type: COMPARATOR
Intervention: Indoor residential concentrations of formaldehyde
Number of subjects: 15
Study 11218421 — intervention group
Group type: COMPARATOR
Intervention: Indoor residential concentrations of acetaldehyde
Number of subjects: 15
Study 11218421 — intervention group
Group type: COMPARATOR
Intervention: Ambient air concentrations of formaldehyde and acetaldehyde
Number of subjects: 15
Study 11218421 — intervention group
Group type: COMPARATOR
Intervention: Workplace concentrations of formaldehyde and acetaldehyde
Number of subjects: 15
Study 11218421 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between personal exposures and indoor residential concentrations
Number of subjects: 15
Study 11218421 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-weighted exposure model
Number of subjects: 15
Study 11218421 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between formaldehyde and acetaldehyde in outdoor microenvironments
Number of subjects: 15
Study 9773732 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination (0.1 ml, 100 microg)
Number of subjects: 26
Study 9773732 — intervention group
Group type: COMPARATOR
Intervention: Control (0.1 ml saline)
Number of subjects: 26
Study 9773732 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 26
Study 9773732 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 26
Study 8011827 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics administration
Number of subjects: 0
Study 3072016 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg
Number of subjects: 40
Study 3072016 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 40
Study 3072016 — intervention group
Group type: COMPARATOR
Intervention: Morphine 10 mg alone
Number of subjects: 40
Study 3072016 — intervention group
Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 40
Study 30511963 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose live attenuated VZV vaccine
Number of subjects: 44
Study 30511963 — intervention group
Group type: COMPARATOR
Intervention: Delayed-start group (control)
Number of subjects: 44
Study 28384010 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 76
Study 28384010 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 76
Study 25574795 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone for the Treatment of Traumatic Brain Injury
Number of subjects: 85
Study 23875707 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic tropism testing (GTT) using geno2pheno algorithm
Number of subjects: 304
Study 23875707 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced-sensitivity Trofile assay (ESTA)
Number of subjects: 304